APA (7th ed.) Citation

P, S., XF, V. P., SM, P., R, D., LP, G., & EP, R. (2020). Nicotinamide riboside with pterostilbene (NRPT) increases NAD+ in patients with acute kidney injury (AKI): A randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI. BMC nephrology, 21(1), 342. https://doi.org/10.1186/s12882-020-02006-1

Chicago Style (17th ed.) Citation

P, Simic, Vela Parada XF, Parikh SM, Dellinger R, Guarente LP, and Rhee EP. "Nicotinamide Riboside with Pterostilbene (NRPT) Increases NAD+ in Patients with Acute Kidney Injury (AKI): A Randomized, Double-blind, Placebo-controlled, Stepwise Safety Study of Escalating Doses of NRPT in Patients with AKI." BMC Nephrology 21, no. 1 (2020): 342. https://doi.org/10.1186/s12882-020-02006-1.

MLA (9th ed.) Citation

P, Simic, et al. "Nicotinamide Riboside with Pterostilbene (NRPT) Increases NAD+ in Patients with Acute Kidney Injury (AKI): A Randomized, Double-blind, Placebo-controlled, Stepwise Safety Study of Escalating Doses of NRPT in Patients with AKI." BMC Nephrology, vol. 21, no. 1, 2020, p. 342, https://doi.org/10.1186/s12882-020-02006-1.